RSV season 2026: who newly qualifies for a second-year shot — and why some newborns still leave hospital unprotected

RSV remains the leading reason young children are hospitalized in the United States. This week, two separate developments matter for parents heading into the 2026–27 respiratory season: the American Academy of Pediatrics widened who should get RSV immunization in their second season, and pediatric groups are still warning that many newborns leave the hospital without the first-season antibody because the dose is not paid for inside a bundled birth bill.

This is not medical advice. Talk with your obstetric and pediatric clinicians about what applies to your pregnancy or child.

Background

RSV (respiratory syncytial virus) is a common winter virus. In healthy older children it often looks like a cold. In infants it can inflame small airways (bronchiolitis) and send babies to the hospital for oxygen, feeding help, or intensive care. For decades the only targeted product was palivizumab, a monthly shot limited to a narrow high-risk group. That product is being discontinued.

Two newer tools changed the picture:

• A maternal vaccine (Pfizer’s Abrysvo) given in late pregnancy so the baby is born with antibodies.
• Long-acting infant antibodies (nirsevimab or clesrovimab) given as a single dose to the baby, ideally before the first RSV season or during the birth hospitalization if the baby is born in season.

Most babies need one path, not both. If the pregnant parent received Abrysvo at the recommended time and the baby is born at least 14 days later, the infant antibody is usually skipped unless there is a special reason.

What changed this week and this season

1. More toddlers in year two are now “high risk”

On September 2, 2026 the AAP published an updated policy (appearing in the November Pediatrics issue). First-season advice is unchanged: infants younger than 8 months who are born during or entering their first RSV season should be protected unless maternal vaccination already covers them.

The change is the second-season list for children ages 8 through 19 months. It already included chronic lung disease of prematurity on medical support, severe immunocompromise, certain cystic fibrosis, and American Indian and Alaska Native children. Newly added groups include:

• Born preterm before 32 weeks, even if they no longer need extra support
• Hemodynamically significant congenital heart disease
• Anatomic lung problems or neuromuscular conditions that raise RSV risk
• Down syndrome or other chromosomal differences that raise severe-disease risk

Eligibility uses chronological age, not “corrected” age for prematurity. Prior nirsevimab or clesrovimab in year one does not cancel year-two eligibility for these high-risk children.

2. Pregnancy timing got a little longer

ACOG’s 2026–27 respiratory guidance now recommends Abrysvo from September 1 through March 1 (previously the window often closed at the end of January). The reason is practical: recent RSV seasons have run later into spring. The dose is still given between 32 weeks 0 days and 36 weeks 6 days, and not within two weeks of a planned delivery.

3. The coverage gap at discharge

AAP and hospital reports this month describe a different problem: the infant antibody can cost around $500, and many insurers treat birth as a bundled payment. Hospitals that cannot bill the dose separately may send babies home unprotected and tell families to “get it at the pediatrician.” That delay is the window RSV uses. Coverage fights are underway; they are not resolved.

Competing viewpoints

Pediatric infectious-disease groups argue the products already cut hospitalizations in the first seasons they were used, and widening year-two criteria follows hospitalization data rather than marketing. They want birth-hospital dosing because that is when almost every baby is reachable.

Hospital finance and some payers treat the antibody as an outpatient drug. Until billing is carved out of the DRG or bundle, nurseries lose money on every dose they give. That is a systems argument, not a safety argument, but it decides whether a 2-day-old actually receives the shot.

Some parents worry about stacking vaccines and antibodies in the first days of life, or prefer to “wait and see” because RSV is common. The counter from AAP/ACOG is that RSV hospitalization risk is highest in the first months; waiting until the first pediatric visit can mean missing the peak.

Federal and AAP schedules have also diverged on other pediatric vaccines this year. For RSV specifically, both still describe maternal vaccine or infant antibody as the core infant strategy. Confirm what your clinic is stocking.

What parents should do now

1. If you are 32–36 weeks pregnant between September and early March, ask obstetrics whether Abrysvo is available this visit. If delivery is expected within two weeks, ask about the infant antibody instead.
2. If you already had Abrysvo this pregnancy and the baby will be born ≥14 days later, you usually do not also need the nursery antibody. Bring the vaccine record to labor and delivery.
3. If you did not get Abrysvo, ask the birth hospital before discharge whether nirsevimab or clesrovimab will be given in the nursery — and who pays. If the answer is “see your pediatrician,” schedule that visit immediately, not “when we get around to it.”
4. If your child is 8–19 months and was very preterm, has significant heart or lung disease, a neuromuscular condition affecting breathing, Down syndrome, or another listed high-risk condition, ask about a second-season dose even if they had an antibody last winter.
5. Palivizumab (Synagis) monthly shots are ending. Do not assume last year’s product is still on the shelf.

What to watch next

• Whether Medicaid and commercial plans carve the infant antibody out of the birth bundle before peak RSV weeks.
• Real-world uptake in the newly added second-season groups.
• How late into spring 2027 RSV activity actually runs — that is the test of ACOG’s longer pregnancy window.
• Local supply of nirsevimab versus clesrovimab; clinics sometimes have one and not the other.

Sources to read with your clinician: AAP policy in Pediatrics (September 2, 2026 online), AAP News coverage of the second-season expansion, ACOG 2026–27 respiratory practice advisory (September 14, 2026), and CDC infant RSV immunization pages. Hospital billing reports from mid-September 2026 describe the discharge-coverage gap.